TY - JOUR T1 - Resistant maltodextrin intake reduces virulent metabolites in the gut environment: randomized control study in a Japanese cohort JF - medRxiv DO - 10.1101/2020.05.25.20112508 SP - 2020.05.25.20112508 AU - Yuichiro Nishimoto AU - Yoshinori Mizuguchi AU - Yuka Mori AU - Masaki Ito AU - Shoko Miyazato AU - Yuka Kishimoto AU - Takuji Yamada AU - Shinji Fukuda Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.05.25.20112508.abstract N2 - Objective In recent years, there have been many reports on the effects of prebiotics on intestinal health. In particular, consuming resistant maltodextrin (RMD) has been reported to be beneficial. However, there has been no comprehensive quantification of the effect of RMD on the intestinal environment. Therefore, this study aimed to quantify the effects of RMD on the intestine, especially the intestinal microbiome and metabolome profiles.Design A randomized, double-blind controlled trial was conducted in 29 Japanese subjects with relatively high hemoglobin A1c (HbA1c). Subjects consumed RMD or placebo twice per day for 24 weeks. Blood and fecal samples were collected before and after intake. The intestinal environment was assessed by a metabologenomics approach combined with 16S rRNA gene-based microbiome and mass spectrometry-based metabologenomics analyses.Results The intake of RMD increased the levels of Bifidobacterium and Fusicatenibacter, and decreased deoxycholate. In addition, intake of the RMD lowered the levels of some virulent metabolites, such as imidazole propionate and trimethylamine, in subjects with an initially high amount of those metabolites.Conclusion RMD may have beneficial effects on the gut environment such as commensal microbiota modulation and reduction of virulence metabolites, known as a causative factor in metabolic disorders. However, its effect partially depends on the gut environmental baseline.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUMIN000023970Clinical Protocols https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027589 Funding StatementNone declared.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Chiyoda Paramedical Care ClinicAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe obtained 16S rRNA gene sequence data are available in the DDBJ DRA (DRA accession number: DRA010060). ER -